 The FDA has extended the review timeline for Alnylam Pharmaceuticals Incs NASDAQ: ALNY marketing application for vutrisiran for transthyretin-mediated ATTR amyloidosis. The updated Prescription Drug User Fee Act PDUFA goal date is July 14. 